Clinical trials acceleration software provider Deep 6 AI has raised $17m through a Series A financing programme led by Point72 Ventures.

The financing round also included participation from GSR Ventures and other strategic partners.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The investment will enable Deep 6 AI to meet the demand from healthcare providers, pharma companies, and contract research organisations for the company’s suite of AI-driven tools.

These tools are designed to optimise clinical trials design and accelerate the recruitment of clinical trials.

Point72 Ventures partner Daniel Gwak said: “Deep 6’s track record in accelerating clinical trials through improved patient recruitment and trial design has resonated strongly with major healthcare providers and trial sponsors, who recognise Deep 6 as the clear leader in this field.”

As part of the investment, Gwak will join the board of Deep 6 AI as one of the directors.

Deep 6 uses AI to recall clinical trial qualification criteria and match against structured and unstructured repositories of patient health data at participating trial sites.

It allows trial sponsors and healthcare providers to find qualified patients before they even invest in recruiting patients and activating trial sites.

Deep 6 AI CEO Wout Brusselaers said: “Point72 Ventures’ emphasis on backing best-in-class category leaders validates Deep 6’s reputation as the product and technology leader in this new industry.

“Their investment will allow us to rapidly scale up to meet the high demand for our software, as health systems recognise the significant opportunity from leveraging AI to turn their research efforts into a growth and profit centre.”

The proceeds from the financing will be used to accelerate the growth of the company’s healthcare providers and trial sponsors’ network.

Part of the funds will also be used to expand Deep 6 AI’s portfolio of AI-native software products.